www.fdanews.com/articles/188220-eu-approves-jazz-vyxeos-for-certain-forms-of-acute-myeloid-leukemia
EU Approves Jazz’ Vyxeos for Certain Forms of Acute Myeloid Leukemia
August 30, 2018
The European Commission approved Jazz’s Vyxeos for treating adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
An advanced liposomal formulation, Vyxeos delivers a synergized combination of daunorubicin and cytarabine to slow tumor growth and kill cancer cells.
AML is a form of blood cancer that begins growth in bone marrow, crowding out healthy cells to spread cancer throughout the body via the bloodstream.